RU2373283C2 - Последовательность днк и рекомбинантное получение основных аллергенов группы 4 из злаковых - Google Patents
Последовательность днк и рекомбинантное получение основных аллергенов группы 4 из злаковых Download PDFInfo
- Publication number
- RU2373283C2 RU2373283C2 RU2006125511/13A RU2006125511A RU2373283C2 RU 2373283 C2 RU2373283 C2 RU 2373283C2 RU 2006125511/13 A RU2006125511/13 A RU 2006125511/13A RU 2006125511 A RU2006125511 A RU 2006125511A RU 2373283 C2 RU2373283 C2 RU 2373283C2
- Authority
- RU
- Russia
- Prior art keywords
- pollen
- dna
- allergens
- dna molecule
- allergies
- Prior art date
Links
- 239000013566 allergen Substances 0.000 title claims abstract description 58
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 title claims description 8
- 241000209504 Poaceae Species 0.000 title abstract description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 41
- 230000007815 allergy Effects 0.000 claims abstract description 39
- 108020004414 DNA Proteins 0.000 claims abstract description 34
- 102000053602 DNA Human genes 0.000 claims abstract description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 19
- 229920001184 polypeptide Polymers 0.000 claims abstract description 17
- 239000013604 expression vector Substances 0.000 claims abstract description 16
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 15
- 239000012634 fragment Substances 0.000 claims abstract description 15
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 238000003745 diagnosis Methods 0.000 claims abstract description 9
- 238000000034 method Methods 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 230000002519 immonomodulatory effect Effects 0.000 claims abstract description 5
- 108020004511 Recombinant DNA Proteins 0.000 claims abstract description 4
- 239000002773 nucleotide Substances 0.000 claims abstract 4
- 125000003729 nucleotide group Chemical group 0.000 claims abstract 4
- 235000013339 cereals Nutrition 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 17
- 239000003814 drug Substances 0.000 claims description 17
- 208000026935 allergic disease Diseases 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 15
- 239000013573 pollen allergen Substances 0.000 claims description 12
- 235000018417 cysteine Nutrition 0.000 claims description 7
- 238000011238 DNA vaccination Methods 0.000 claims description 6
- 108020004705 Codon Proteins 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 230000001024 immunotherapeutic effect Effects 0.000 claims description 4
- 238000003259 recombinant expression Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 150000001945 cysteines Chemical class 0.000 claims 1
- 230000000977 initiatory effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 abstract description 28
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 abstract description 7
- 238000000338 in vitro Methods 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000001727 in vivo Methods 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract description 3
- 206010048908 Seasonal allergy Diseases 0.000 abstract description 2
- 201000004338 pollen allergy Diseases 0.000 abstract description 2
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 1
- 229960004784 allergens Drugs 0.000 description 34
- 235000018102 proteins Nutrition 0.000 description 21
- 235000007340 Hordeum vulgare Nutrition 0.000 description 9
- 108010076504 Protein Sorting Signals Proteins 0.000 description 8
- 101150033839 4 gene Proteins 0.000 description 7
- 241000209219 Hordeum Species 0.000 description 7
- 230000000774 hypoallergenic effect Effects 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 241000209056 Secale Species 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 102000001708 Protein Isoforms Human genes 0.000 description 5
- 108010029485 Protein Isoforms Proteins 0.000 description 5
- 241000209140 Triticum Species 0.000 description 5
- 235000021307 Triticum Nutrition 0.000 description 5
- 210000004899 c-terminal region Anatomy 0.000 description 5
- 125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 5
- 229940046528 grass pollen Drugs 0.000 description 5
- 230000009257 reactivity Effects 0.000 description 5
- 241001329985 Triticeae Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000009169 immunotherapy Methods 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 238000010188 recombinant method Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 244000052363 Cynodon dactylon Species 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 240000004296 Lolium perenne Species 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000002741 site-directed mutagenesis Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- 108020003589 5' Untranslated Regions Proteins 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 239000010267 Allergoid Substances 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 240000004585 Dactylis glomerata Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 240000003857 Holcus lanatus Species 0.000 description 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 241000746983 Phleum pratense Species 0.000 description 1
- 241000209049 Poa pratensis Species 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000013567 aeroallergen Substances 0.000 description 1
- 229940074608 allergen extract Drugs 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 239000013574 grass pollen allergen Substances 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 238000000734 protein sequencing Methods 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Botany (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10359351A DE10359351A1 (de) | 2003-12-16 | 2003-12-16 | DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden |
| DE10359351.9 | 2003-12-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2006125511A RU2006125511A (ru) | 2008-01-27 |
| RU2373283C2 true RU2373283C2 (ru) | 2009-11-20 |
Family
ID=34683486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2006125511/13A RU2373283C2 (ru) | 2003-12-16 | 2004-12-01 | Последовательность днк и рекомбинантное получение основных аллергенов группы 4 из злаковых |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US7935347B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2261336B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP4960102B2 (cg-RX-API-DMAC7.html) |
| CN (2) | CN103305531A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE501257T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004299600A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0417736A (cg-RX-API-DMAC7.html) |
| CA (3) | CA2549573C (cg-RX-API-DMAC7.html) |
| DE (2) | DE10359351A1 (cg-RX-API-DMAC7.html) |
| ES (3) | ES2363015T3 (cg-RX-API-DMAC7.html) |
| PL (3) | PL2261337T3 (cg-RX-API-DMAC7.html) |
| PT (3) | PT2261336E (cg-RX-API-DMAC7.html) |
| RU (1) | RU2373283C2 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005059136A2 (cg-RX-API-DMAC7.html) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2774709C2 (ru) * | 2016-05-24 | 2022-06-22 | Монсанто Текнолоджи Ллс | Регуляторные элементы растений и варианты их применения |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10359351A1 (de) * | 2003-12-16 | 2005-07-21 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden |
| US9920101B2 (en) | 2014-03-31 | 2018-03-20 | Boehringer Ingelheim Vetmedica Gmbh | Modular antigen transportation molecules and uses therof |
| KR20180061338A (ko) | 2015-09-30 | 2018-06-07 | 베링거잉겔하임베트메디카게엠베하 | 동물에서의 개선된 모듈러 항원 수송 분자 및 이의 용도 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2001130165A (ru) * | 1999-04-23 | 2003-07-20 | Мерк Патент Гмбх | Последовательность ДНК и получение аллергена злаковых рекомбинантным способом |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5762943A (en) * | 1996-05-14 | 1998-06-09 | Ribi Immunochem Research, Inc. | Methods of treating type I hypersensitivity using monophosphoryl lipid A |
| DE19918682A1 (de) * | 1999-04-23 | 2000-10-26 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung eines Graminaen-Allergens |
| US7214786B2 (en) * | 2000-12-14 | 2007-05-08 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| EP1402037A1 (en) * | 2001-06-22 | 2004-03-31 | Syngenta Participations AG | Plant genes involved in defense against pathogens |
| AUPR779201A0 (en) * | 2001-09-20 | 2001-10-11 | University Of Melbourne, The | Immunotherapeutic and immunoprophylactic reagents |
| WO2003025008A2 (en) | 2001-09-21 | 2003-03-27 | Affinium Pharmaceuticals, Inc. | Bacterial polypeptides involved in protein processing |
| CA2491038C (en) * | 2002-06-25 | 2017-04-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Dna sequence and preparation of grass pollen allergen phl p4 by recombinant methods |
| DE10359351A1 (de) * | 2003-12-16 | 2005-07-21 | Merck Patent Gmbh | DNA-Sequenz und rekombinante Herstellung von Gruppe-4 Majorallergenen aus Getreiden |
-
2003
- 2003-12-16 DE DE10359351A patent/DE10359351A1/de not_active Withdrawn
-
2004
- 2004-12-01 DE DE502004012294T patent/DE502004012294D1/de not_active Expired - Lifetime
- 2004-12-01 PT PT100096775T patent/PT2261336E/pt unknown
- 2004-12-01 EP EP10009677.5A patent/EP2261336B1/de not_active Expired - Lifetime
- 2004-12-01 CN CN2013102182194A patent/CN103305531A/zh active Pending
- 2004-12-01 CA CA2549573A patent/CA2549573C/en not_active Expired - Fee Related
- 2004-12-01 PL PL10009678T patent/PL2261337T3/pl unknown
- 2004-12-01 ES ES04803421T patent/ES2363015T3/es not_active Expired - Lifetime
- 2004-12-01 JP JP2006544263A patent/JP4960102B2/ja not_active Expired - Fee Related
- 2004-12-01 PT PT04803421T patent/PT1709177E/pt unknown
- 2004-12-01 CA CA2945267A patent/CA2945267A1/en not_active Abandoned
- 2004-12-01 CA CA2873261A patent/CA2873261C/en not_active Expired - Fee Related
- 2004-12-01 EP EP04803421A patent/EP1709177B1/de not_active Expired - Lifetime
- 2004-12-01 RU RU2006125511/13A patent/RU2373283C2/ru not_active IP Right Cessation
- 2004-12-01 AU AU2004299600A patent/AU2004299600A1/en not_active Abandoned
- 2004-12-01 ES ES10009678.3T patent/ES2443302T3/es not_active Expired - Lifetime
- 2004-12-01 US US10/583,089 patent/US7935347B2/en not_active Expired - Fee Related
- 2004-12-01 ES ES10009677.5T patent/ES2442951T3/es not_active Expired - Lifetime
- 2004-12-01 PL PL04803421T patent/PL1709177T3/pl unknown
- 2004-12-01 BR BRPI0417736-3A patent/BRPI0417736A/pt not_active Application Discontinuation
- 2004-12-01 PT PT100096783T patent/PT2261337E/pt unknown
- 2004-12-01 CN CNA2004800372314A patent/CN1894410A/zh active Pending
- 2004-12-01 EP EP10009678.3A patent/EP2261337B1/de not_active Expired - Lifetime
- 2004-12-01 PL PL10009677T patent/PL2261336T3/pl unknown
- 2004-12-01 WO PCT/EP2004/013664 patent/WO2005059136A2/de not_active Ceased
- 2004-12-01 AT AT04803421T patent/ATE501257T1/de active
-
2010
- 2010-11-16 US US12/947,361 patent/US9309297B2/en not_active Expired - Fee Related
-
2015
- 2015-12-17 US US14/972,633 patent/US20170246317A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2001130165A (ru) * | 1999-04-23 | 2003-07-20 | Мерк Патент Гмбх | Последовательность ДНК и получение аллергена злаковых рекомбинантным способом |
Non-Patent Citations (1)
| Title |
|---|
| DATA BASE, GenBank, * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2774709C2 (ru) * | 2016-05-24 | 2022-06-22 | Монсанто Текнолоджи Ллс | Регуляторные элементы растений и варианты их применения |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9789178B2 (en) | DNA sequence, and recombinant preparation of the grass pollen allergen Lol p 4 | |
| US9556241B2 (en) | DNA sequence and preparation of grass pollen allergen Phl p 4 by recombinant methods | |
| US9309297B2 (en) | DNA sequence, and recombinant preparation of group 4 major allergens from cereals | |
| US7241450B1 (en) | DNA sequence and recombinant production of a Gramineae allergen | |
| AU2011202726B2 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals | |
| AU2013204574B2 (en) | DNA-sequence and recombinant production of group 4 major allergens from cereals | |
| JP2008504004A5 (cg-RX-API-DMAC7.html) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20171202 |